title: HIV-antigens charged on phosphorus dendrimers as tools for tolerogenic dendritic cells-based immunotherapy.
abstract: OBJECTIVE
  The objective was to study if cationic phosphorus dendrimers can be used as DC-based vaccine or adjuvant in anti-HIV-1 vaccine development when associated with HIV-1 derived peptides.
  
  
  METHODS
  The HIV derived peptides uptake in DC and the phenotype of iDC and mDC were studied using Flow Cytometry analysis. Migration of mDC was evaluated by an in vitro chemotaxis assay. Allogenic T-cells proliferative response induced by DC was studied using Flow Cytometry assays. Cytokines production was analysed by Diaclon DIAplex Th1/Th2/Inflammation kit.
  
  
  RESULTS
  All phosphorus dendrimers showed the ability to deliver HIV-derived peptides in DC. The phosphorus dendrimers from second and third generations induced important changes in phenotype. Moreover, the treatment of mDC with the second generation dendrimer and derivated dendriplexes modified cellular migratory properties, altered their capacity to stimulate allogenic naïve T cells in vitro and impeded the production of pro-inflammatory cytokines.
  
  
  CONCLUSIONS
  The phosphorus dendrimers cannot be used as vaccines because they would not have the ability to induce an immune response. The cationic phosphorus dendrimers associated with HIV-derived peptides have the ability to deliver peptides as non-viral vectors. However, there are other potential therapeutic applications of these compounds, for instance as topical antiinflammatory agents, as compounds for allograft rejection or autoimmune diseases and as agents inducing specific tolerance with antigen-loaded DC against allergy reaction. Nevertheless, these applications need to be evaluated.
authors.forename: Enrique
authors.initials: E
authors.lastname: Vacas-Córdoba
authors.forename: Hugo
authors.initials: H
authors.lastname: Bastida
authors.forename: Marjorie
authors.initials: M
authors.lastname: Pion
authors.forename: Aurélien
authors.initials: A
authors.lastname: Hameau
authors.forename: Maksim
authors.initials: M
authors.lastname: Ionov
authors.forename: Maria
authors.initials: M
authors.lastname: Bryszewska
authors.forename: Anne Marie
authors.initials: AM
authors.lastname: Caminade
authors.forename: Jean Pierre
authors.initials: JP
authors.lastname: Majoral
authors.affiliation: Laboratorio InmunoBiologia Molecular, Hospital General Universitario Gregorio Maranon, Madrid, Spain. mmunoz.hgugm@gmail.com.
authors.forename: María-Ángeles
authors.initials: MÁ
authors.lastname: Muñoz-Fernández
mesh_terms: D002465:Cell Movement; D016207:Cytokines / Q000378:metabolism; D050091:Dendrimers / Q000737:chemistry / Q000627:therapeutic use*; D003713:Dendritic Cells / Q000276:immunology* / Q000378:metabolism; D015488:HIV Antigens / Q000276:immunology*; D006801:Humans; D007167:Immunotherapy; D010758:Phosphorus / Q000737:chemistry*
chemical_list: D016207:Cytokines; D050091:Dendrimers; D015488:HIV Antigens; D010758:Phosphorus